PMID- 36527321
OWN - NLM
STAT- MEDLINE
DCOM- 20230314
LR  - 20230314
IS  - 1464-3502 (Electronic)
IS  - 0735-0414 (Linking)
VI  - 58
IP  - 2
DP  - 2023 Mar 10
TI  - Baclofen Combined With Psychosocial Care is Useful and Safe in Alcohol-Related 
      Cirrhosis Patients: A Real-Life Multicenter Study.
PG  - 117-124
LID - 10.1093/alcalc/agac065 [doi]
AB  - BACKGROUND: Alcohol-related cirrhosis is a frequent and difficult-to-treat 
      disease. Despite the low hepatic metabolism of baclofen, data on its use in this 
      subgroup are scarce. The French multicenter Observatory of patients treated with 
      Baclofen for Alcohol DEpendence real-life cohort assessed: (a) prescription 
      modalities of baclofen in liver units; (b) safety profile of baclofen; and (c) 
      declared alcohol intake, biological markers of excessive alcohol intake and 
      hepatic function at 12 months. METHODS: All consecutive patients with cirrhosis 
      who received baclofen to reduce alcohol consumption or maintain abstinence were 
      prospectively included. Psychosocial management was always associated. Clinical 
      and biological data were collected every 3 months for 1 year. RESULTS: Between 
      November 2013 and December 2016, 71 in- or outpatients were included from 10 
      liver units. Of the patients, 25% had ascites. After 12 months, 52 patients (73%) 
      were still being followed, and 41 (57.7%) were still receiving baclofen at a mean 
      dosage of 75 mg/day (r30-210). The overall declared consumption decreased from 
      100.2 to 14.7 g/day (P < 0.0001), and 29 patients (40.8%) reached abstinence. 
      Significant improvement in the usual biomarkers of excessive alcohol intake (AST, 
      GGT and MCV) and liver function (Prothrombin ratio (PTr), albumin levels) were 
      observed. The usual side effects such as drowsiness were frequent (22%) but no 
      serious adverse events (AEs) or overt encephalopathy related to baclofen was 
      reported. CONCLUSION: In this 1-year follow-up series, baclofen was combined with 
      psychosocial treatment in patients with cirrhosis and was well tolerated. This 
      treatment was associated with a significant decrease in declared alcohol 
      consumption as well as improvement in hepatic function.
CI  - (c) The Author(s) 2022. Medical Council on Alcohol and Oxford University Press. All 
      rights reserved.
FAU - Barrault, Camille
AU  - Barrault C
AD  - Liver, Digestive Disease and Addiction Unit, CH Intercommunal, Creteil 83056, 
      France.
FAU - Alqallaf, Shuaib
AU  - Alqallaf S
AD  - Liver, Digestive Disease and Addiction Unit, CH Intercommunal, Creteil 83056, 
      France.
FAU - Lison, Hortensia
AU  - Lison H
AD  - Liver and Digestive Diseases Nutrition and Addiction Department, GHPSO, Creil 
      60100, France.
FAU - Lamote-Chaouche, Isabelle
AU  - Lamote-Chaouche I
AD  - Addiction Unit, Liver, Digestive Disease and Addiction Unit, GHEF, Meaux 44730, 
      France.
FAU - Bourcier, Valerie
AU  - Bourcier V
AD  - Liver Unit, AP-HP, Hopitaux Universitaires Paris Seine Saint-Denis, Bobigny 
      93143, France.
FAU - Laugier, Joelle
AU  - Laugier J
AD  - Liver, Digestive Disease and Addiction Unit, CH Delafontaine, Saint Denis, 
      Bobigny 93200, France.
FAU - Thevenot, Thierry
AU  - Thevenot T
AD  - Liver Unit and Intensive Care Unit, Hopital Jean Minjoz, 25030 Besancon Cedex, 
      France.
AD  - CIC-1431 INSERM, CHU de Besancon, Besancon 25030, France.
FAU - Labarriere, Damien
AU  - Labarriere D
AD  - Liver, Digestive Disease and Addiction Unit, CH Regional, Orleans 75008, France.
FAU - Ripault, Marie-Pierre
AU  - Ripault MP
AD  - Liver, Digestive Disease and Addiction Unit, CH, Narbonne 11108, France.
FAU - Le Gruyer, Antonia
AU  - Le Gruyer A
AD  - Liver, Digestive Disease and Addiction Unit, CH Yves Le Foll, Saint Brieuc 22000, 
      France.
FAU - Costentin, Charlotte
AU  - Costentin C
AD  - Liver Unit, CHU Grenoble 38043, France.
FAU - Behar, Veronique
AU  - Behar V
AD  - Liver, Digestive Disease and Addiction Unit, CH Intercommunal, Creteil 83056, 
      France.
FAU - Hagege, Herve
AU  - Hagege H
AD  - Liver, Digestive Disease and Addiction Unit, CH Intercommunal, Creteil 83056, 
      France.
FAU - Jung, Camille
AU  - Jung C
AD  - CRC CH Intercommunal, Creteil 94010, France.
FAU - Cadranel, Jean-Francois
AU  - Cadranel JF
AD  - Liver and Digestive Diseases Nutrition and Addiction Department, GHPSO, Creil 
      60100, France.
CN  - ANGH OBADE Group
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - England
TA  - Alcohol Alcohol
JT  - Alcohol and alcoholism (Oxford, Oxfordshire)
JID - 8310684
RN  - H789N3FKE8 (Baclofen)
SB  - IM
MH  - Humans
MH  - Baclofen/therapeutic use
MH  - *Psychiatric Rehabilitation
MH  - Liver Cirrhosis, Alcoholic/complications
MH  - *Alcoholism/psychology
MH  - Alcohol Drinking/psychology
MH  - Liver Cirrhosis/complications
OTO - NOTNLM
OT  - alcohol related liver disease
OT  - alcohol use disorder
OT  - anti abuse drug
OT  - baclofen
OT  - cirrhosis
EDAT- 2022/12/18 06:00
MHDA- 2023/03/15 06:00
CRDT- 2022/12/17 04:32
PHST- 2022/06/09 00:00 [received]
PHST- 2022/11/10 00:00 [revised]
PHST- 2022/11/14 00:00 [accepted]
PHST- 2022/12/18 06:00 [pubmed]
PHST- 2023/03/15 06:00 [medline]
PHST- 2022/12/17 04:32 [entrez]
AID - 6918726 [pii]
AID - 10.1093/alcalc/agac065 [doi]
PST - ppublish
SO  - Alcohol Alcohol. 2023 Mar 10;58(2):117-124. doi: 10.1093/alcalc/agac065.